{"entity":{"id":"nct04115306","kind":"trial","name":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Phoenix Molecular Designs, active and no longer recruiting.","summary":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT04115306 by Phoenix Molecular Designs, with 61 participants enrolled, started 2019-11-14 and due to reach its primary completion in 2026-12. Interventions recorded: PMD-026 and fulvestrant.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04115306","url":"https://clinicaltrials.gov/study/NCT04115306"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["fulvestrant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04115306","phase":"1/2","setting":"Ph 1/1b/2 Multicenter, Open-Label, FIH Dose Esc & Dose Exp Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients With Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer","sponsor":"Phoenix Molecular Designs","enrolled":61,"outcomes":[]},"route":"/trials/nct04115306/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"}]}}